The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer.

ABSTRACT:

Background

An effect of non-oncology medications on cancer outcome has been proposed. In this study, we aimed to systematically examine the impact of commonly prescribed non-oncology drugs on clinical risk and on the genomic risk [based on the Oncotype DX recurrence score (RS)] in early breast cancer (BC).

Experimental design

We collected data on clinical risk (stage and grade), genomic risk (Oncotype DX RS), and on non-oncology medications administered to 1423 patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative BC during the month of their surgery. The influence of various medications on clinical and genomic risks was evaluated by statistical analysis.

Results

Out of the multiple drugs we examined, levothyroxine was significantl

SUBMITTER: Waissengrin B 

PROVIDER: S-EPMC9808449 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature